Drug
Bnt329
Bnt329: highest development phase Phase 1/2, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT329 NCT07186842 | Phase 1/2 | Advanced Solid Cancers |
Latest
No recent events.
Follow Bnt329 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.